Development of a chimeric c-Src kinase and HDAC inhibitor

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 779-783

  Ko, Kristin S ^a   Steffey, Michael E ^a   Brandvold, Kristoffer R ^a   Soellner, Matthew B ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

c Src; chimera; combination therapy; HDAC; kinase

Indexed keywords

DASATINIB; HISTONE DEACETYLASE; PANOBINOSTAT; VORINOSTAT;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYCLOADDITION; CYTOTOXICITY; DOWN REGULATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 84881467331     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400175d     Document Type: Article

References (25)

1. Thomas, S. M.; Brugge, J. S. Cellular functions regulated by Src family kinases Annu. Rev. Cell Dev. Biol. 1997, 13, 513-609
2. Martin, G. S. The hunting of the Src Nat. Rev. Mol. Cell Biol. 2001, 2, 467-475
3. Zhan, S.; Huang, W.-C.; Li, P.; Guo, H.; Poh, S.-B.; Brady, S. W.; Xiong, Y.; Tseng, L.-M.; Li, S.-H.; Ding, Z.; Sahin, A. A.; Esteva, F. J.; Hortobagyi, G. N.; Yu, D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Nat. Med. 2011, 17, 461-469
4. Brandvold, K. R.; Steffey, M. E.; Fox, C. C.; Soellner, M. B. Development of a highly selective c-Src kinase inhibitor ACS Chem. Biol. 2012, 7, 1393-1398
5. Pirrone, V.; Thakkar, N.; Jacobson, J. M.; Wingdahl, B.; Krebs, F. C. Combinatorial approaches to the prevention and treatment of HIV-1 infection Antimicrob. Agents Chemother. 2011, 55, 1831-1842
6. Harries, A. D.; Dye, C. Tuberculosis Ann Top. Med. Parasitol. 2006, 5-6, 415-431
7. Bouza, E.; Muñoz, P. Monotherapy versus combination therapy for bacterial infections Med. Clin. North Am. 2000, 84, 1357-1389
8. Dancey, J. E.; Chen, H. X. Strategies for optimizing combinations of molecularly targeted anticancer agents Nat. Rev. Drug Discovery 2006, 5, 649-659
9. Zheng, X.; Resnick, R. J.; Shalloway, D. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTPα and Src RNAi Int. J. Cancer 2008, 122, 1999-2007
10. Atadja, P. Development of the pan-HDAC inhibitor panobinostat (LBH589): Successes and challenges Cancer Lett. 2009, 280, 233-241
11. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 2006, 5, 769-784
12. Kostyniuk, C.; Dehm, S.; Batten, D.; Bonham, K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of tissue deacetylases Oncogene 2002, 21, 6340-6347
13. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25, 84-90
14. Zimmermann, G. R.; Lehár, J.; Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts Drug Discovery Today 2007, 12, 34-42
15. Muller, Y.; Milton, M. The determination and interpretation of the therapeutic index in drug development Nat. Rev. Drug Discovery 2012, 11, 751-761
16. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.-J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)- N -hydroxyheptanamide (CUDC-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer J. Med. Chem. 2010, 53, 2000-2009
17. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGFRβ, and histone deacetylases J. Med. Chem. 2009, 52, 2265-2344
18. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity J. Med. Chem. 2010, 53, 8546-8601
19. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: From bench to clinic J. Med. Chem. 2008, 51, 1505-1534
20. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: Diverse chemical function from a few good reactions Angew. Chem., Int. Ed. 2001, 40, 2004-2021
21. Chen, P.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2008, 16, 4839-4892
22. Zhang, L.; Chen, X. G.; Xue, P.; Sun, H. Y. Y.; Williams, I. D.; Sharpless, K. B.; Fokin, V. V.; Jia, G. C. Ruthenium-catalyzed cycloaddition of alkynes and organic azides J. Am. Chem. Soc. 2005, 127, 15998-15999
23. Wang, Q.; Cahill, S. M.; Blumenstein, M.; Lawrence, D. S. Self-reporting fluorescent substrates of protein tyrosine kinases J. Am. Chem. Soc. 2006, 128, 1808-1809
24. Shultz, B. E.; Misialek, S.; Wu, J.; Tang, J.; Conn, M. T.; Tahilramani, R.; Wong, L. Kinetics and comparative reactivity of human class I and IIb histone deacetylases Biochemistry 2004, 43, 11083-11091
25. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen Nat. Rev. Cancer 2006, 6, 813-823